Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03696303
Recruitment Status : Not yet recruiting
First Posted : October 4, 2018
Last Update Posted : January 14, 2019
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
This prospective case-control study aims to evaluate the utility and establish laboratory thresholds for a multi-serotype urine antigen test for the diagnosis of pneumococcal community acquired pneumonia in children 5 years of age or younger in Guatemala.

Condition or disease Intervention/treatment
Community-acquired Pneumonia Streptococcus Pneumoniae Infection Other: Urinary antigen detection assay

Layout table for study information
Study Type : Observational
Estimated Enrollment : 960 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala
Estimated Study Start Date : March 2019
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Cases
Suspected community-acquired bacterial pneumonia
Other: Urinary antigen detection assay
Screening for Ag level in S. pneumoniae urinary antigen detection assay.

Controls
Healthy children, age-matched to enrolled cases
Other: Urinary antigen detection assay
Screening for Ag level in S. pneumoniae urinary antigen detection assay.




Primary Outcome Measures :
  1. Urinary antigen detection cut-points for invasive S. pneumoniae disease [ Time Frame: Within 48 hours ]
    To determine Cut-Points to discriminate a positive or negative urine antigen test that differentiates invasive disease versus the carriage state


Secondary Outcome Measures :
  1. Detection of S. pneumoniae serotypes using Urinary antigen detection assay [ Time Frame: Within 48 hours ]
    To determine the sensitivity and specificity of the Luminex xMPA pneumococcal UAD in the identification of S. pneumoniae serotypes (PCV13 serotypes) in children with radiologically confirmed CAP


Biospecimen Retention:   Samples With DNA
Urine Blood Nasopharyngeal swab samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   31 Days to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Children 5 years of age or younger with either community-acquired pneumonia (cases) or health children (controls).
Criteria

CASES:

Inclusion Criteria:

  • Age older than 1 month (31 days) and up to 71 months and 28 days.
  • Diagnosis of radiologically confirmed pneumonia per WHO criteria in the ED or hospital within 48 hours of hospital admission
  • Signed informed consent by parents or legal guardian to participate in the study

Exclusion Criteria:

  • Known immunodeficiency
  • Major congenital malformation (e.g., hemodynamically compromised congenital heart malformation or any malformation leading to recurrent pneumonia) or serious chronic disorder
  • Significant neurological disorder
  • Hospitalization within the previous 30 days for pneumonia or respiratory infection
  • Use of parenteral antibiotics for current illness (leading to diagnosis of pneumonia)
  • Transferred to the study hospital after already being hospitalized at a different location for ≥ 48 hours

CONTROLS:

Inclusion Criteria:

  • Age 1 to 71 months and signed informed consent by parents or legal guardian

Exclusion Criteria:

  • Known immunodeficiency
  • Major congenital malformation (e.g., hemodynamically compromised congenital heart malformation or any malformation leading to recurrent pneumonia) or serious chronic disorder
  • Significant neurological disorder
  • Fever or suspicion of community-acquired pneumonia or other respiratory infectious disease (symptoms of cough, congestion, tachypnea, indrawing, etc.)
  • Hospitalization within the previous 30 days for pneumonia or respiratory infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03696303


Contacts
Layout table for location contacts
Contact: Sara R Saporta-Keating, MD 720-777-1084 sara.saporta-keating@childrenscolorado.org
Contact: Daniel Olson, MD 720-724-9558 Daniel.Olson@childrenscolorado.org

Sponsors and Collaborators
University of Colorado, Denver
Pfizer
Investigators
Layout table for investigator information
Principal Investigator: Edwin Asturias, MD University of Colorado - Anschutz Medical Campus

Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT03696303     History of Changes
Other Study ID Numbers: 18-0737
First Posted: October 4, 2018    Key Record Dates
Last Update Posted: January 14, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Colorado, Denver:
Streptococcus pneumoniae
Pneumonia
Community-acquired
Pediatric
Urine antigen

Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Pneumococcal Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Streptococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections